Ra Capital Management, L.P. Mirati Therapeutics, Inc. Transaction History

Ra Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $28.8 Million - $65.1 Million	-734,343 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $26.8 Million - $53.3 Million	353,297 Added 92.72%	734,343 $60.4 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $50.3 Million - $72.5 Million	381,046 New	381,046 $55.9 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.